Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genetic Technologies ( (AU:GTG) ) has shared an announcement.
Genetic Technologies Limited has announced that director Steven Nicols ceased to be a director of the company effective 24 March 2026. The final director’s interest notice confirms that Nicols held no shares directly in his own name, while an entity with which he is associated, Benelong Capital Partners Pty Ltd, holds 26,493,450 ordinary shares, signaling that a substantial indirect shareholding remains on the register despite his board departure.
The disclosure clarifies the separation of Nicols’ direct role from his indirect financial exposure, which may reassure investors about transparency in governance and ownership. While the notice involves no change to the company’s capital structure, it formalizes a board-level transition and highlights the continued presence of a large institutional holder linked to the former director, which could influence future shareholder dynamics and voting outcomes.
The most recent analyst rating on (AU:GTG) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Genetic Technologies stock, see the AU:GTG Stock Forecast page.
More about Genetic Technologies
Genetic Technologies Limited is a biotechnology company listed on the ASX. It operates in the genetics sector, with activities centered on genetic technologies and related scientific and commercial applications. The company’s shareholder base includes institutional investors such as Benelong Capital Partners Pty Ltd, reflecting external capital participation in its equity structure.
Technical Sentiment Signal: Sell
Current Market Cap: A$5.67M
See more insights into GTG stock on TipRanks’ Stock Analysis page.